[晚期甲状腺癌的系统疗法--最新进展]。

IF 0.9 4区医学 Q3 OTORHINOLARYNGOLOGY

Laryngo-rhino-otologie Pub Date : 2024-09-01 Epub Date: 2024-02-12 DOI:10.1055/a-2249-2239

Tim Brandenburg, Yara Maria Machlah, Dagmar Führer-Sakel

{"title":"[晚期甲状腺癌的系统疗法--最新进展]。","authors":"Tim Brandenburg, Yara Maria Machlah, Dagmar Führer-Sakel","doi":"10.1055/a-2249-2239","DOIUrl":null,"url":null,"abstract":"Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"637-642"},"PeriodicalIF":0.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Systemic therapies for advanced thyroid cancer - an update].\",\"authors\":\"Tim Brandenburg, Yara Maria Machlah, Dagmar Führer-Sakel\",\"doi\":\"10.1055/a-2249-2239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.\",\"PeriodicalId\":17965,\"journal\":{\"name\":\"Laryngo-rhino-otologie\",\"volume\":\" \",\"pages\":\"637-642\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laryngo-rhino-otologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2249-2239\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngo-rhino-otologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2249-2239","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

基于III期临床研究，德国批准了四种多激酶抑制剂（MKI）用于治疗进展期放射性碘难治性分化型甲状腺癌（rrDTC）和甲状腺髓样癌（MTC）。直到最近，基于随机试验 COSMIC-311，Cabozantinib 才被批准作为晚期 RrDTC 的二线治疗方案。作为首个标签内选择性RET抑制剂，赛乐替尼（Selpercatinib）在RET突变的晚期MTC（一线）和RET融合的rrDTC（二线）中显示出良好的疗效，且副作用较小。目前的 ATA 指南总结了 ATC 治疗的变化和新方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Systemic therapies for advanced thyroid cancer - an update].

Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects. Changes and new approaches for the treatment of ATC have been summarised in the current ATA guidelines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Laryngo-rhino-otologie 医学-耳鼻喉科学

CiteScore

1.00

自引率

30.00%

发文量

1399

审稿时长

6-12 weeks

期刊介绍： Die Laryngo-Rhino-Otologie ist die deutschsprachige Fachzeitschrift für Ärzte in Klinik und Praxis mit Fokus auf die Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie. Die Laryngo-Rhino-Otologie bringt die Themen, die Sie wirklich interessieren und in der täglichen Arbeit unterstützen: Kurze, leicht lesbare Beiträge, interessante Rubriken und Originalarbeiten mit Relevanz für Ihre Arbeit.